Paclitaxel+carboplatin

DRUG2 trials

Sponsors

Japanese Gynecologic Oncology Group, Shengjing Hospital

Conditions

Breast CancerEpithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer

Phase 3

Trial of Tri-weekly TJ Versus Weekly TJ for Stage II-IV Mullerian Carcinoma

CompletedNCT00226915

Japanese Gynecologic Oncology GroupEpithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer

Start: 2003-04-30End: 2012-06-30Updated: 2020-02-17

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

RecruitingNCT04137653

Shengjing HospitalBreast Cancer

Start: 2021-07-19End: 2026-11-30Target: 1498Updated: 2021-07-20

Related Papers

Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial.

2013-08-13338 citations

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

2009-09-18488 citations